The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
Advances in antibody-drug conjugate (ADC) technology and identification of new antigen targets are repositioning ADCs as a promising therapeutic platform for metastatic castration-resistant prostate cancer (mCRPC). This review summarizes recent progress in ADC payload and linker chemistry, highlights membrane antigens in prostate cancer that have demonstrated encouraging antitumor activity in clinical trials, and addresses strategies to mitigate off-target toxicity. These advances position ADCs to transform the therapeutic landscape of mCRPC.
Authors
- Ariana Santopietro
- Claire Lin
- Anthony Mega (ORCID: https://orcid.org/0009-0008-6409-9325)
- Elias S. Hyams (ORCID: https://orcid.org/0009-0002-8346-7388)
- Benedito A. Carneiro (ORCID: https://orcid.org/0000-0002-5468-1126)
- Matthew J. Hadfield (ORCID: https://orcid.org/0000-0002-8768-0082)
- Wafik S. El‐Deiry (ORCID: https://orcid.org/0000-0002-9577-8266)
- Rahul Aggarwal (ORCID: https://orcid.org/0000-0001-7003-7982)
- Liang Cheng
- Galina Lagos
Institutions
- University of California, San Francisco (US)
- Brown University (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
Publication Details
- Journal
- npj Precision Oncology
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1038/s41698-025-01131-0
- Citations
- 4
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 6.07